Ebru İnci ÇOŞKUN, Salim SEZER, İsmail DAĞ, Ercan YILMAZ, Yavuz Tahsin AYANOĞLU

Vitronectin and prolactin levels of cervicovaginal irrigation liquid in preterm birth risk evaluation

Aim: The objective of this study is to determine the predictive role of cervical length, cervicovaginal irrigation liquid vitronectin andprolactin levels in preterm birth.Material and Methods: A total of 73 pregnant women between 24-34th gestational week were included and the study populationwas divided into two groups as: term birth group (n=54) and preterm birth(n=19). Birth weeks, weight and methods were noted. Theirrigation fluid has been collected from posterior fornix and vitronectin levels are detected by Enzyme-linked-immunosorbent-assaymethod.Results: Vitronectin were higher in preterm group as compared to controls [90 (78-98) vs 16 (9-41) ng/ml, p

PDF

___

1. Slattery MM, Morrison JJ. Preterm delivery. Lancet 2002;360:1489-97.
2. Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2005. National Vital Statistics Reports 2006;55 .
3. Çiçek MN, Akyürek C, Çelik Ç, et al. Preterm Eylem. Kadın Hastalıkları ve Doğum Bilgisi Ankara: Güneş Kitabevi 2006: 727-37.
4. Hofman PI, Regan F, Jackson WE, et al. Premature birth and later insülin resistance. N Engl J Med 2004; 351:2179.
5. Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. N Engl J Med 2007;356:2053.
6. Ingelfinger JR: Prematurity and the legacy of intrauterine stres. N Engl J Med 2007;356:2093.
7. Kaijser M, Bonamy AK, Akre O, et al. Perinatal risk factors for diabetes in later life. Diabetes 2009;58:523.
8. Ginsberg HG, Goldsmith JP, Stedman CM. Survival of a 380 g infant. N Engl J Med Jun 1990;322;1753-4.
9. Annas GJ: Extremely preterm birth and parental authority to refuse treatment-the case of Sidney Miller. N Engl J Med 2004;35:2118.
10. Mercer BM, Goldenberg RL, Meis PJ, et al. The preterm prediction study: prediction of preterm premature rupture of membranes through clinical findings and ancillary testing. Am J Obstet Gynecol 2000;183:738-45.
11. Sunagawa S, Takagi K, OnoK, et al. Comparison of biochemical markers and cervical length for predicting preterm delivery. J Obstet Gynaecol Res 2008;34:812- 9.
12. Riddick DH, Luciano AA, Kusmik W, et al. De novo synthesis of prolactin by human decidua. Life Sci 1978;23:1913-21.
13. Maaskant RA, Bogic LV, Glger S, et al. The human prolactin receptor in the fetal membranes, decidua, and placenta. J clin Endocrinol Metab 1996;81:396- 405.
14. O’Brien JM, Peeler GH, Pitts DW, et al. Cervicovaginal prolactin: a marker for spontaneous preterm delivery. Am J Obstet Gynecol 1994;171:1107-11.
15. Alawad ZM, Al-Omary HL. Maternal and cord blood prolactin level and pregnancy complications. Pak J Med Sci 2019;35:1122-7.
16. Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. N Engl J Med 1996;334:567-72.
17. Jenne D, Stanley KK. ‘Nucleotide sequence and organization of the human S-protein gene: repeating motifs in the “pexin” family and a model for their evolution’. Biochemistry 1987;26:6735-42.
18. Xu D, Baburaj K, Peterson CB, et al. ‘Model for the three-dimensional structure of vitronectin: predictions for the multi-domain protein from threading and docking’. Proteins 2001;44:312.
19. Felding-Habermann B, Cheresh DA. ‘Vitronectin and its receptors’ Curr OpinCell Biol 1993;5:864-8.
20. McKeown-Longo PJ, Panetti TS. Structure and function of vitronectin. Trends Glycosci Glycotechnol 1996;8:327-40.
21. Preissner KT, Seiffert d. ‘Role of vitronectin and its receptors in haemostasis and vascular remodeling’. Thromb Res 1998;89:1-21.
22. Bergmann S, Lang A, Rohde M, et al. Integrinlinked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells. J Cell Sci 2009;122:256-67.
23. Mayasundari A, Whittemore NA, Serpersu EH, et al. The solution structure of the N-terminal domain of human vitronectin: Proximal sites that regulate fibrinolysis and cell migration. The J Biological Chemistry 2004; 279:29359-366.
24. Preissner KT. Structure and biological role of vitronectin. Ann Rev Cell Biology 1991;7:275-310.
25. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annual Review of Cell and Developmental Biology 1995;11:549-99.
26. Palecek SP, Schmidt CE, Lauffenburger DA, et al. Integrin Dynamics on the tail region of migrating fibroblasts. J Cell Science 1996;109:941-52.
27. Uhm JH, Gladson CL, Rao JS. The role of integrins in the malignant phenotype of gliomas. Frontiers in Bioscience 1999;4:188-99.
28. Guvenal T, Kantas E, Erselcan T, et al. Beta-human chorionic gonadotropin and prolactin assays in cervicovaginal secretions as a predictor of preterm delivery. Int J of Gynecol and Obstetrics 2001;75:229- 34.
29. Doyle NM, Monga M. Role of ultrasound in screening patients at risk for preterm delivery. Obstet Gynecol Clin North Am 2004;31:125-39.
30. Iams JD, Casal D, McGregor JA, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995;173:141-5.
31. Gomez R, Romero R, Medina L, et al. Cervicovaginal fibronectin improves the prediction of preterm delivery based on sonographic cervical length in patients with preterm uterine contractions and intact membranes. Am J Obstet Gynecol 2005;192:350-9.
32. Revah A, Hannah ME, Sue AQAK. Fetal fibronectin as a predictor of preterm birth: an overview. Am J Perinatol 1998;15:613-21.
33. Honest H, Bachmann LM, Gupta JK, et al. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002;325:301.
34. Buduneli N. Dişetinin ekstrasellüler matriksi. EÜ Dişhek Fak Derg 2001;22:1-12.
35. Patel SS, Ludmir J. Drugs for the treatment and prevention of preterm labor. Clin Perinatol 2019;46: 159-72.
36. Kolialexi A, Tsangaris GT, Sifakis S, et al. Plasma biomarkers for the identification of women at risk for early-onset preeclampsia. Expert Rev Proteomics 2017;14:269-76.
37. Balcı Ekmekçi Ö, Ekmekçi H, Güngör Z, et al. Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia. Arch Gynecol Obstet 2015;292:53-8.
38. Blumenstein M, Prakash R, Cooper GJ, North RA; SCOPE Consortium. Aberrant processing of plasma vitronectin and high-molecular-weight kininogen precedes the onset of preeclampsia. Reprod Sci 2009; 16:1144-52.
39. Hammes HP, Brownlee M, Jonczyk A, et al. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Medicine 1996;2:529-33.
40. Mitjans F, Sander D, Adan J, et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nüde mice. J Cell Sci 1995;108:2825-38.